<html><head></head><body><h1>HYDROXYprogesterone</h1><p class="drug-subtitle"><b>Class:</b> Progestins<br/>
<b>Chemical Name:</b> 17-[(1-Oxohexyl)oxy]-pregn-4-ene-3,20-dione<br/>
<b>Molecular Formula:</b> C<sub>27</sub>H<sub>40</sub>O<sub>4</sub><br/>
<b>CAS Number:</b> 630-56-8<br/>
<b>Brands:</b> Makena</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Synthetic progestin.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for HYDROXYprogesterone</h2><h3>Preterm Birth Risk Reduction</h3><p>Reduction of risk of preterm birth in women with a singleton pregnancy having a history of singleton spontaneous preterm birth (designated an orphan drug by FDA for this use).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Efficacy determined based on improvement in proportion of women who delivered at &lt;37 weeks of gestation; direct clinical benefit (e.g., improvement in neonatal morbidity and mortality) not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy demonstrated only in women with a prior spontaneous singleton birth; not intended for use in women with multiple gestations or other risk factors for preterm birth.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>ACOG recommends offering progesterone supplementation for prevention of recurrent preterm birth to women with a singleton pregnancy and a prior spontaneous preterm birth at &lt;37 weeks of gestation due to spontaneous preterm labor or premature rupture of membranes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">HYDROXYprogesterone Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Prior to commercial availability, another formulation containing the active ingredient was available to patients from pharmacists who compounded the injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>FDA currently not intending to take action against such pharmacies compounding an injection on a valid prescription for an individual patient and in accordance with appropriate standards for compounding sterile products.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Prior to commercial availability, another formulation containing the active ingredient was available to patients from pharmacists who compounded the injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>FDA currently not intending to take action against such pharmacies compounding an injection on a valid prescription for an individual patient and in accordance with appropriate standards for compounding sterile products.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Administer by slow IM injection ( ≥1 minute) by a clinician.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Patients should not self-administer the drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Withdraw appropriate dose from the vial using a 3-mL syringe with an 18-gauge needle; prior to administration, replace the 18-gauge needle with a 21-gauge, 1.5-inch needle.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>After preparing the skin, administer by slow IM injection into the upper outer quadrant of the gluteus maximus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Apply pressure to the injection site to minimize bruising and swelling.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hydroxyprogesterone caproate injection is a clear, yellow, viscous, oily solution; discard if solution is cloudy or solid particles appear.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard any unused portions 5 weeks after first use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>250 mg once weekly (every 7 days); begin therapy between 16 weeks, 0 days and 20 weeks, 6 days of gestation; continue until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>No specific dosage recommendations at this time.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for HYDROXYprogesterone</h2><h3>Contraindications</h3><ul>
<li>
<p>Current thrombosis or thromboembolic disorders or history of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Thromboembolic Disorders under Cautions.)</p>
</li>
<li>
<p>Known or suspected breast cancer, other hormone-sensitive cancer, or history of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Undiagnosed abnormal vaginal bleeding unrelated to pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Cholestatic jaundice of pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Jaundice under Cautions.)</p>
</li>
<li>
<p>Liver tumors (benign or malignant) or active liver disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Uncontrolled hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hypertension under Cautions.)</p>
</li>
</ul><p>Current thrombosis or thromboembolic disorders or history of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Thromboembolic Disorders under Cautions.)</p><p>Known or suspected breast cancer, other hormone-sensitive cancer, or history of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Undiagnosed abnormal vaginal bleeding unrelated to pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cholestatic jaundice of pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Jaundice under Cautions.)</p><p>Liver tumors (benign or malignant) or active liver disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Uncontrolled hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Hypertension under Cautions.)</p><h3>Warnings/Precautions</h3><p>Discontinue if an arterial or deep venous thrombotic or thromboembolic event occurs; contraindicated in patients with current thrombosis or thromboembolic disorders or history of these conditions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Allergic reactions, including urticaria, pruritus, and angioedema, reported with hydroxyprogesterone caproate and other products containing castor oil; consider discontinuing the drug if such reactions occur.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Decreased glucose tolerance observed in some patients receiving progestins; mechanism not known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Carefully monitor patients with prediabetes or diabetes during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Progestational agents may cause fluid retention; carefully monitor patients with conditions aggravated by fluid retention (e.g., preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor patients with a history of clinical depression during therapy; discontinue drug if clinical depression recurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Carefully monitor patients who develop jaundice during therapy; consider whether benefit of use warrants continuation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated in cholestatic jaundice of pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Carefully monitor patients who develop hypertension during therapy; consider whether benefit of use warrants continuation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Contraindicated in patients with uncontrolled hypertension.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category B.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>No adequate and well-controlled studies in women during first trimester of pregnancy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Teratogenic risks to infants following in utero exposure to the drug not demonstrated in a study of pregnant women receiving the drug during their second and third trimesters, as well as in a follow-up safety study of their infants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not intended to stop active preterm labor; effect of drug for this use unknown.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Detectable amounts of progestins identified in milk of women receiving progestins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; No adverse effects of progestins on breastfeeding performance or on health, growth, or development of infants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue drug at 37 weeks of gestation or upon delivery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not indicated for use in pediatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Safety and efficacy not established in pediatric patients &lt;16 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Limited number of women &lt;18 years of age studied; safety and efficacy expected to be the same in women ≥16 years of age compared with those ≥18 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not evaluated in women ≥65 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;11&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Not intended for use in postmenopausal women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Safety and efficacy not established in postmenopausal women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Contraindicated in patients with liver tumors (benign or malignant) or active liver disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Effect of hepatic impairment on pharmacokinetics of the drug not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Special Populations under Pharmacokinetics.)</p><p>Effect of renal impairment on pharmacokinetics of the drug not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>Injection site reactions (pain, swelling, pruritus, nodule), urticaria, pruritus, nausea, diarrhea.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for HYDROXYprogesterone</h2><p>No formal drug interaction studies to date.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes</h3><p>Metabolized principally by CYP isoenzymes 3A4 and 3A5;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; unlikely to inhibit activity of CYP2C8, 2C9, 2C19, 2D6, 2E1, and 3A4.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In vitro study showed increased metabolic rate of CYP isoenzymes 1A2, 2A6, and 2B6 by approximately 80, 150, and 80%, respectively; clinical importance not fully elucidated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Metabolic induction potential not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Drugs metabolized by CYP isoenzymes 1A2, 2A6, and 2B6 may have increased metabolism if used concomitantly with hydroxyprogesterone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Acetaminophen</p><p>Metabolism of acetaminophen may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bupropion</p><p>Metabolism of bupropion may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Clozapine</p><p>Metabolism of clozapine may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Efavirenz</p><p>Metabolism of efavirenz may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Halothane</p><p>Metabolism of halothane may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Methadone</p><p>Metabolism of methadone may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Nicotine</p><p>Metabolism of nicotine may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Theophylline</p><p>Metabolism of theophylline may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Tizanidine</p><p>Metabolism of tizanidine may be increased&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">HYDROXYprogesterone Pharmacokinetics</h2><p>Pharmacokinetics of the 250-mg dose of hydroxyprogesterone caproate not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Absorption</h3><p>Peak serum concentrations attained after 3–7 days following a single IM injection of 1 g of the drug in nonpregnant women; time to peak serum concentrations was 4.6 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Detectable amounts of progestins identified in the milk of women receiving progestins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Binds extensively to plasma proteins, including albumin and corticosteroid-binding globulins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Metabolized by human hepatocytes via both phase I and II reactions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Metabolized principally by CYP isoenzymes 3A4 and 3A5; caproic acid group remains intact during metabolism.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Undergoes extensive reduction, hydroxylation, and conjugation; conjugated metabolites include sulfated, glucuronidated, and acetylated products.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Excreted in urine and feces, principally as conjugated metabolites and also as free steroids.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Approximately 50 and 30% of dose recovered in feces and urine, respectively, following IM administration in pregnant women at 10–12 weeks of gestation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>7.8 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Hepatic impairment: Effect on pharmacokinetics of drug not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Hepatic impairment may reduce elimination of the drug because of extensive metabolism of drug.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Renal impairment: Effect on pharmacokinetics of drug not evaluated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>15–30°C; store upright in original carton and protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Discard any unused portions 5 weeks after first use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard if cloudy or solid particles appear.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>Synthetic progestin; produced by esterification of 17α-hydroxyprogesterone, a naturally occurring metabolite of progesterone, with caproic acid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Has strong progestogenic activity; appears to produce a longer lasting and more potent progestational effect on endometrium than progesterone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Does not appear to have androgenic, antiandrogenic, estrogenic, or glucocorticoid activity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Mechanism of action in reducing the risk of recurrent preterm birth not known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Synthetic progestin; produced by esterification of 17α-hydroxyprogesterone, a naturally occurring metabolite of progesterone, with caproic acid.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has strong progestogenic activity; appears to produce a longer lasting and more potent progestational effect on endometrium than progesterone.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Does not appear to have androgenic, antiandrogenic, estrogenic, or glucocorticoid activity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mechanism of action in reducing the risk of recurrent preterm birth not known.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Importance of patients reading the manufacturer’s patient information prior to initiation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of pain, soreness, swelling, itching, or bruising at injection site.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinicians if increased discomfort, oozing of blood or fluid, or inflammatory reaction at injection site occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are breast-feeding or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, vitamins, and herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p>
</li>
</ul><p>Importance of patients reading the manufacturer’s patient information prior to initiation of therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of pain, soreness, swelling, itching, or bruising at injection site.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of informing clinicians if increased discomfort, oozing of blood or fluid, or inflammatory reaction at injection site occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are breast-feeding or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, vitamins, and herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Prior to commercial availability, another formulation containing the active ingredient was available to patients from pharmacists who compounded the injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See General under Dosage and Administration.)</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Parenteral</p><p>Injection, for IM use</p><p>250 mg/mL</p><p>Makena<sup></sup></p><p>Ther-Rx</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions January 27, 2012. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><h2>References</h2><p>1. Ther-Rx Corporation. Makena<sup></sup> (hydroxyprogesterone caproate) injection prescribing information. St. Louis, MO; 2011 Feb.</p><p>2. Food and Drug Administration. FDA Application: Search Orphan Drug Designations and Approvals. Rockville, MD. From FDA website. Accessed 2011 Sep 2. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm</p><p>3. Meis PJ, Klebanoff M, Thom E et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. <i>N Engl J Med</i>. 2003; 348:2379-85. http://www.ncbi.nlm.nih.gov/pubmed/12802023?dopt=AbstractPlus</p><p>4. Northen AT, Norman GS, Anderson K et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. <i>Obstet Gynecol</i>. 2007; 110:865-72. http://www.ncbi.nlm.nih.gov/pubmed/17906021?dopt=AbstractPlus</p><p>5. Sharma S, Ou J, Strom S et al. Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention of preterm birth. <i>Drug Metab Dispos</i>. 2008; 36:1896-902. http://www.ncbi.nlm.nih.gov/pubmed/18573861?dopt=AbstractPlus</p><p>6. Yan R, Fokina V, Hankins GD et al. The effect of esterases on 17alpha-hydroxyprogesterone caproate. <i>Am J Obstet Gynecol</i>. 2008; 198:229.e1-5.</p><p>7. Meis PJ, Society for Maternal-Fetal Medicine. 17 hydroxyprogesterone for the prevention of preterm delivery. <i>Obstet Gynecol</i>. 2005; 105:1128-35. http://www.ncbi.nlm.nih.gov/pubmed/15863556?dopt=AbstractPlus</p><p>8. Schindler AE. Role of progestogens for the prevention of premature birth. <i>J Steroid Biochem Mol Biol</i>. 2005; 97:435-8. http://www.ncbi.nlm.nih.gov/pubmed/16198556?dopt=AbstractPlus</p><p>9. Food and Drug Administration. FDA statement: FDA statement on Makena. 2011 Mar 30. From FDA website. Accessed 2011 Aug 29. http://www.fda.gov/newsEvents/Newsroom/PressAnnouncements/ucm249025.htm</p><p>10. Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. <i>Obstet Gynecol</i>. 2008; 112:963-5. http://www.ncbi.nlm.nih.gov/pubmed/18827143?dopt=AbstractPlus</p><p>11. Ther-Rx Corporation, St. Louis, MO: Personal communication.</p><h2>More about hydroxyprogesterone</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>148 Reviews</li>
<li>Drug class: progestins</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Hydroxyprogesterone Intramuscular &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Hydroxyprogesterone Caproate Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Premature Labor</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>